Semaglutide - Generic Drug Details

What are the generic drug sources for semaglutide and what is the scope of patent protection?

Semaglutide is the generic ingredient in three branded drugs marketed by Novo and is included in four NDAs. There are thirty-seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Semaglutide has four hundred and fifty patent family members in thirty-eight countries.

Two suppliers are listed for this compound.

Summary for semaglutide

International Patents:	450
US Patents:	37
Tradenames:	3
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	470
Patent Applications:	2,758
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for semaglutide
What excipients (inactive ingredients) are in semaglutide?	semaglutide excipients list
DailyMed Link:	semaglutide at DailyMed

Recent Clinical Trials for semaglutide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Wenzhou Medical University	PHASE2
St. James's Hospital, Ireland	PHASE2
Leiden University Medical Center	PHASE3

See all semaglutide clinical trials

Pharmacology for semaglutide

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Anatomical Therapeutic Chemical (ATC) Classes for semaglutide

A10BJ	Glucagon-like peptide-1 (GLP-1) analogues
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for SEMAGLUTIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYBELSUS	Tablets	semaglutide	1.5 mg, 4 mg and 9 mg	213051	1	2025-12-11
RYBELSUS	Tablets	semaglutide	3 mg, 7 mg and 14 mg	213051	1	2024-07-15
OZEMPIC	Injection	semaglutide	2 mg/3 mL	209637	1	2024-04-11
OZEMPIC	Injection	semaglutide	8 mg/3 mL	209637	1	2022-12-21
WEGOVY	Injection	semaglutide	0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL	215256	1	2022-10-20
OZEMPIC	Injection	semaglutide	2 mg/1.5 mL and 4 mg/3 mL	209637	7	2021-12-06

US Patents and Regulatory Information for semaglutide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-003	Jun 4, 2021		RX	Yes	Yes	8,129,343		Y	Y
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-002	Jun 4, 2021		RX	Yes	Yes	8,536,122		Y	Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-006	Dec 9, 2024		RX	Yes	Yes	11,833,248		Y
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-003	Dec 22, 2025		RX	Yes	No	12,239,739
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019		RX	Yes	Yes
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019		RX	Yes	Yes	12,514,822
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019		RX	Yes	Yes	11,759,503		Y

Expired US Patents for semaglutide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-001	Jun 4, 2021	8,536,122
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019	10,376,652
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-003	Mar 28, 2022	8,579,869
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017	8,579,869
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017	9,616,180
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022	9,616,180
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022	8,114,833

EU/EMA Drug Approvals for semaglutide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novo Nordisk A/S	Wegovy	semaglutide	EMEA/H/C/005422Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to	Authorised	no	no	no	2022-01-06
Novo Nordisk A/S	Ozempic	semaglutide	EMEA/H/C/004174Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2018-02-08
Novo Nordisk A/S	Rybelsus	semaglutide	EMEA/H/C/004953Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2020-04-03

International Patents for semaglutide

Country	Patent Number	Title	Estimated Expiration
Malaysia	198425	GLP-1 COMPOSITIONS AND USES THEREOF
Mexico	369259	DOSIFICACION ORAL DE COMPUESTOS PEPTIDO SIMILAR AL GLAUCON-1 (GLP-1). (ORAL DOSING OF GLP-1 COMPOUNDS.)
Japan	7576910
Russian Federation	2506957	МЕХАНИЗМ УМЕНЬШЕНИЯ УСТАНОВЛЕННОЙ ДОЗЫ ДЛЯ ВЗВОДИМОГО ШПРИЦА-РУЧКИ (MECHANISM OF REDUCING ESTABLISHED DOSE FOR COCKED PREFILLED SYRINGE)
Hungary	E066356
Russian Federation	2014141700	КОМПОЗИЦИИ GLP-1 ПЕПТИДОВ И ИХ ПОЛУЧЕНИЕ
Japan	2020529467

Supplementary Protection Certificates for semaglutide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	132018000000262	Italy		PRODUCT NAME: SEMAGLUTIDE(OZEMPIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1251, 20180212
1863839	22/2018	Austria		PRODUCT NAME: SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839	661	Finland
1863839	C01863839/01	Switzerland		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018
1863839	CR 2018 00019	Denmark		PRODUCT NAME: SEMAGLUTID; REG. NO/DATE: EU/1/17/1251 20180212
1863839	2018C/016	Belgium		PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839	SPC/GB18/023	United Kingdom		PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208

Market Dynamics and Financial Trajectory for Semaglutide

Last updated: March 25, 2026

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes and obesity. Originally developed by Novo Nordisk, it is marketed under brand names such as Ozempic, Wegovy, and Rybelsus. The drug has gained regulatory approval in several markets for multiple indications and demonstrates a substantial revenue growth profile due to rising prevalence of target conditions.

Market Overview

Size and Growth Rate

The global GLP-1 receptor agonists market, valued at approximately USD 10 billion in 2022, is projected to reach USD 23 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.7%. Semaglutide accounts for a significant share, driven by its efficacy in both diabetes management and weight loss.

Indications and Scope

• Type 2 Diabetes: Approved in 2017 (Ozempic) with a focus on glycemic control.
• Obesity: Approved as Wegovy in 2021, targeting obesity management.
• Off-label and expanded uses: Early-stage exploration for cardiovascular and other metabolic conditions.

Key Market Drivers

• Increasing prevalence of type 2 diabetes, projected to reach 700 million cases globally by 2045 (IDF, 2022).
• Rising obesity rates, currently over 650 million adults worldwide (WHO, 2021).
• Favorable clinical data showing superior weight loss efficacy compared to competitors.
• Regulatory approvals expanding indications and markets.

Competitive Landscape

Major Players

• Novo Nordisk: Dominates with Ozempic, Wegovy, Rybelsus.
• Eli Lilly: Entered with tirzepatide, a dual GIP/GLP-1 agonist, offering a competitive alternative.
• Others: AstraZeneca (dulaglutide), Bayer (lispro).

Market Share Estimates (2022)

Company	Market Share (%)	Key Products
Novo Nordisk	65	Ozempic, Wegovy, Rybelsus
Eli Lilly	20	Tirzepatide
Others	15	Dulaglutide, alternatives

Patent and Exclusivity Status

• Semaglutide patents extend into the late 2020s, with biosimilar interest emerging as patents face expiry.

Pricing and Reimbursement

• List Price: USD 1,350 for a monthly Ozempic dose; USD 1,500–1,700 for Wegovy in the US.
• Reimbursement: Widely covered in developed markets; cost is a barrier in emerging regions.
• Pricing Trends: Slight reductions observed in response to biosimilar entries and market competition.

Revenue and Financial Trajectory

Historical Revenue (2020–2022)

Year	Revenue (USD billion)	Growth (%)
2020	3.4	—
2021	6.4	88.2
2022	9.8	53.1

Forecast for 2023–2030

• 2023: Estimated USD 12.5 billion revenue driven by increased adoption and expanded indications.
• 2025: Potential USD 20 billion if growth persists at an annual rate of approximately 15–20%.
• 2030: Revenue could approach USD 30 billion, assuming patent protection longevity, market expansion, and uptake in emerging markets.

Key Revenue Contributors

• Diabetes treatment (~60% revenue share)
• Obesity management (~35%)
• Cardiovascular and other indications (~5%)

Note: Growth influenced by market penetration, biosimilar competition, and regulatory changes.

Regulatory and Policy Factors

• Approval Dates: Ozempic (2017, US), Wegovy (2021, US), Rybelsus (2019, US).
• Biosimilar Entry: Expected post-patent expiry (late 2020s), could impact pricing and market share.
• Health Authority Policies: Favorable towards innovative obesity and diabetes therapies; some countries implementing value-based pricing.

Key Challenges and Risks

• Patent expiries threaten market exclusivity in late 2020s.
• Competition from tirzepatide, which shows superior weight loss and glycemic control.
• Reimbursement restrictions in cost-sensitive markets.
• Manufacturing complexities associated with peptide-based biologics.

Opportunities

• Growing demand in emerging economies.
• Expansion into additional indications such as cardiovascular diseases.
• Development of combination therapies to enhance efficacy.

Conclusion

Semaglutide maintains a dominant position in the GLP-1 receptor agonist space. Revenue growth will depend on patent protections, competitive dynamics, and market acceptance. The drug's versatility and proven efficacy drive a strong financial trajectory, with potential for significant expansion in the coming years.

Key Takeaways

• The GLP-1 market is projected to nearly double by 2030, with semaglutide leading.
• Revenue reached USD 9.8 billion in 2022, with anticipated growth to USD 30 billion by 2030.
• Competition from tirzepatide introduces pricing and market share risks post-patent expiry.
• Expansion in emerging markets and indications forms key opportunities.
• Patent expiration and biosimilar entry are the primary risks to sustained dominance.

FAQs

1. When will semaglutide’s patent expire?
   Patent protections extend into the late 2020s, with patent expiry expected around 2028–2029.

2. How does tirzepatide compare to semaglutide?
   Tirzepatide is a dual GIP/GLP-1 receptor agonist demonstrating superior weight loss and glycemic control in clinical trials, potentially challenging semaglutide's market share.

3. What growth catalysts exist for semaglutide after 2023?
   Expanded approvals, increased adoption in emerging markets, and new indications like cardiovascular disease.

4. What are the pricing trends for semaglutide?
   Prices remain stable but may decline post-patent expiry or in markets with biosimilar competition.

5. Are biosimilars imminent?
   Biosimilars are likely post-2028; initial developments have begun, but regulatory approvals may take several years.

---

References

[1] International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th Edition.
[2] World Health Organization. (2021). Obesity and overweight factsheet.
[3] MarketWatch. (2023). Global GLP-1 receptor agonist market report.
[4] Novo Nordisk Annual Reports (2020–2022).
[5] U.S. Food and Drug Administration. (2017–2022). Drug approvals and patent information.